Commit Biologics launches with €16m seed financing to pioneer complement system activation to treat cancer and autoimmune disease

Commit Biologics United Kingdom United States of America Denmark Massachusetts Ontario California

Financing led by Bioqube Ventures and Novo Holdings Commit is pioneering a novel approach to activating the complement component of the immune system to treat cancer and autoimmune diseases Its unique bispecific technology (BiCE™) engages the complement system, unleashing its power to selectively kill target cells Spin-out from Aarhus University in Denmark, a world leader in complement structural biologyView original content:https://www.prnewswire.co.uk/news-releases/commit-biologics-launches-with-16m-seed-financing-to-pioneer-complement-system-activation-to-treat-cancer-and-autoimmune-disease-302140040.html